Roger Pebody

Paris

Medical Writer and Editor at Freelance

Managing editor at https://t.co/kmS1qeZfvx, views are my own.

Featured in: Favicon

aidsmap.com Favicon

thelancet.com Favicon

thebody.com Favicon

thebodypro.com Favicon

hivandhepatitis.com Favicon

medcentral.com Favicon

medscape.com (+1)

Articles

Simpler PrEP services - fewer check-ups, online care - work as well as the standard approach

1 month ago | aidsmap.com | Roger Pebody

Estimated reading time 3 minutes While some countries have already shifted to less intensive monitoring requirements for PrEP users, a Dutch study has now provided evidence that it’s OK to test for sexually transmitted infections (STIs) every six months, to have clinic appointments at the same rhythm and for services to be delivered online. Simplified, less burdensome services had just as good outcomes as the standard of care.
Disparidades en los cálculos de riesgo cardiovascular para pacientes con virus de inmunodeficiencia humana

1 month ago | espanol.medscape.com | Roger Pebody

Una calculadora de riesgo cardiovascular utilizada habitualmente por los profesionales médicos subestima el riesgo para las mujeres y las personas afrodescendientes que viven con infección por virus de inmunodeficiencia humana en los países de ingresos altos, mientras que sobreestima el riesgo para las personas con dicho virus en los países de ingresos bajos y medios.[1] Las puntuaciones de riesgo son un factor clave en las recomendaciones de las guías para la prescripción de estatinas y...
Thigh ART Injections May Open the Door for Self-Injection

1 month ago | medscape.com | Roger Pebody

Cabotegravir and rilpivirine (cabenuva), the only complete HIV treatment regimen delivered by injection, could be given by intramuscular injection to the thigh rather than the gluteal muscles, research suggests. Currently, the intramuscular injections are provided by healthcare professionals. The new research might make self-injection of this antiretroviral therapy (ART) a more feasible option.
Cardiovascular Risk Calculators Fail Some Patients With HIV

2 months ago | medscape.com | Roger Pebody

A cardiovascular risk calculator routinely used by physicians underestimates the risk for women and Black people living with HIV in high-income countries, while it overestimates risk for people living with HIV in low- and middle-income countries. Risk scores are a key factor in guideline recommendations for prescription of statins and determine how many providers approach counseling with a specific patient.
Artificial intelligence powers HIV testing services in Kenya

2 months ago | thelancet.com | Roger Pebody

Data gathered over the past two decades of the HIV response are now informing efforts to use artificial intelligence to assess HIV risk and improve care in Kenya. Roger Pebody reports.
Future of HIV Post-Exposure Prophylaxis Weighed by Experts at IDWeek Medical Conference

Dec 10, 2024 | medcentral.com | Roger Pebody

Pre-exposure prophylaxis (PrEP) is at the heart of modern HIV prevention strategies, but what about post-exposure prophylaxis (PEP)? Does it still have a role to play? At this year's IDWeek conference, Darrell H.S. Tan, MD, FRCPC, argued that it does. “PEP is critical part of a comprehensive menu of prevention options,” said Tan, an infectious disease physician at St. Michael’s Hospital in Toronto, during a session devoted to debating key questions in HIV medicine.
Current Knowledge and Recent Research

Nov 25, 2024 | thebodypro.com | Roger Pebody

Chronic pain is an important comorbidity in people living with HIV, and Jessica Merlin, M.D., Ph.D., is among the world’s leading experts on the subject. Merlin points to two key factors accentuating the priority of addressing pain in HIV care. For one thing, it is highly prevalent: Somewhere between 25% and 85% of people living with HIV report pain that lasts longer than three months, she said (i.e., it persists beyond the typical period of tissue injury and repair).
Future of HIV Post-Exposure Prophylaxis Weighed by Experts at IDWeek Medical Conference

Nov 22, 2024 | thebodypro.com | Roger Pebody

Pre-exposure prophylaxis (PrEP) is at the heart of modern HIV prevention strategies, but what about post-exposure prophylaxis (PEP)? Does it still have a role to play? At this year's IDWeek conference, Darrell H.S. Tan, M.D., FRCPC, argued that it does. “PEP is critical part of a comprehensive menu of prevention options,” said Tan, an infectious disease physician at St. Michael’s Hospital in Toronto, during a session devoted to debating key questions in HIV medicine.
Injectable PrEP comes to southern Africa

Oct 28, 2024 | thelancet.com | Roger Pebody

As interest in long-acting HIV prevention surges, the first few months of experience with cabotegravir in sub-Saharan Africa provide lessons for scale-up. Roger Pebody reports. In February, 2024, the Zambian Ministry of Health introduced long-acting cabotegravir for pre-exposure prophylaxis (PrEP), the first African country to do so outside of a research study.
People need pathways from PEP to PrEP - and back again

Mar 5, 2024 | aidsmap.com | Roger Pebody

Estimated reading time 4 minutes Services providing post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) need to build stronger connections between these two ways of preventing HIV infection, so as to help people who’ve used one method to access the other, according to experts at the Conference on Retroviruses and Opportunistic Infections (CROI 2024).